M Spaziani1,2, A Semeraro3,4, E Bucci5, F Rossi3,4, M Garibaldi5, M A Papassifachis3,4, C Pozza4, A Anzuini3, A Lenzi3, G Antonini5, A F Radicioni3,4. 1. Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Policlinico Umberto I, Sapienza University of Rome, Level - 1, Room 33, Rome, Italy. matteo.spaziani@uniroma1.it. 2. Centre for Rare Diseases, Policlinico Umberto I, Rome, Italy. matteo.spaziani@uniroma1.it. 3. Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Policlinico Umberto I, Sapienza University of Rome, Level - 1, Room 33, Rome, Italy. 4. Centre for Rare Diseases, Policlinico Umberto I, Rome, Italy. 5. Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Rome, Italy.
Abstract
PURPOSE: Myotonic dystrophy type 1 (DM1) is a genetic disorder caused by CTG expansion in the DMPK gene. The aim was to investigate the endocrine and metabolic aspects of DM1. PATIENTS AND METHODS: Retrospective, case-control study. We compared pituitary, thyroid, adrenal, gonadal and liver function and glycolipid metabolism of 63 DM1 patients against 100 control subjects. Given age-related differences, 2 further subgroups were created to investigate the pituitary-gonadal axis: < 41 (1a) and ≥ 41 (1b) years old for male subjects and < 46 (2a) and ≥ 46 (2b) years old for female subjects. Testicular and thyroid ultrasounds were also performed in the DM1 group. RESULTS: FT3 and FT4 were significantly lower in DM1 men than controls, while for both males and females, thyroglobulin, ACTH and cortisol were significantly higher in the DM1 group. Gonadotropin levels were significantly higher and inhibin B and DHEA-S levels significantly lower in DM1 patients than controls for both male subgroups. Testosterone and SHBG were significantly higher in controls than in patients for subgroup 1a. Prolactin was significantly higher in patients in subgroups 1b, while testosterone was lower in subgroup 2a than in age-matched female controls. A correlation between the number of CTG repeats and the percentage of male hypogonadal subjects was found. Finally, there was a worse glucose and lipid pattern and significantly higher transaminase and gamma-GT levels in both male and female patients. CONCLUSIONS: The high frequency of endocrine and metabolic abnormalities in DM1 highlights the importance of endocrine monitoring to enable the prompt initiation of a suitable therapy.
PURPOSE:Myotonic dystrophy type 1 (DM1) is a genetic disorder caused by CTG expansion in the DMPK gene. The aim was to investigate the endocrine and metabolic aspects of DM1. PATIENTS AND METHODS: Retrospective, case-control study. We compared pituitary, thyroid, adrenal, gonadal and liver function and glycolipid metabolism of 63 DM1 patients against 100 control subjects. Given age-related differences, 2 further subgroups were created to investigate the pituitary-gonadal axis: < 41 (1a) and ≥ 41 (1b) years old for male subjects and < 46 (2a) and ≥ 46 (2b) years old for female subjects. Testicular and thyroid ultrasounds were also performed in the DM1 group. RESULTS: FT3 and FT4 were significantly lower in DM1 men than controls, while for both males and females, thyroglobulin, ACTH and cortisol were significantly higher in the DM1 group. Gonadotropin levels were significantly higher and inhibin B and DHEA-S levels significantly lower in DM1 patients than controls for both male subgroups. Testosterone and SHBG were significantly higher in controls than in patients for subgroup 1a. Prolactin was significantly higher in patients in subgroups 1b, while testosterone was lower in subgroup 2a than in age-matched female controls. A correlation between the number of CTG repeats and the percentage of male hypogonadal subjects was found. Finally, there was a worse glucose and lipid pattern and significantly higher transaminase and gamma-GT levels in both male and female patients. CONCLUSIONS: The high frequency of endocrine and metabolic abnormalities in DM1 highlights the importance of endocrine monitoring to enable the prompt initiation of a suitable therapy.
Authors: A F Radicioni; N Tahani; M Spaziani; A Anzuini; C Piccheri; A Semeraro; L Tarani; A Lenzi Journal: J Endocrinol Invest Date: 2012-08-29 Impact factor: 4.256
Authors: M De Antonio; C Dogan; D Hamroun; M Mati; S Zerrouki; B Eymard; S Katsahian; G Bassez Journal: Rev Neurol (Paris) Date: 2016-09-21 Impact factor: 2.607
Authors: M Spaziani; S Granato; N Liberati; F M Rossi; N Tahani; C Pozza; D Gianfrilli; G Papi; A Anzuini; A Lenzi; L Tarani; A F Radicioni Journal: J Endocrinol Invest Date: 2020-05-06 Impact factor: 4.256
Authors: Tiago Mateus; Filipa Martins; Alexandra Nunes; Maria Teresa Herdeiro; Sandra Rebelo Journal: Int J Environ Res Public Health Date: 2021-02-12 Impact factor: 3.390
Authors: M Spaziani; C Tarantino; C Pozza; A Anzuini; F Panimolle; G Papi; D Gianfrilli; A Lenzi; A F Radicioni Journal: J Endocrinol Invest Date: 2020-10-24 Impact factor: 4.256